170 related articles for article (PubMed ID: 23552479)
1. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
LaPresto L; Cranmer L; Morrison L; Erickson CP; Curiel-Lewandrowski C
JAMA Dermatol; 2013 Mar; 149(3):279-81. PubMed ID: 23552479
[No Abstract] [Full Text] [Related]
2. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
Chon SY; Sambrano BL; Geddes ER
J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
[TBL] [Abstract][Full Text] [Related]
3. Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?
Sachse MM; Fenchel K; Wagner G
J Dtsch Dermatol Ges; 2014 Aug; 12(8):721-3. PubMed ID: 24981739
[No Abstract] [Full Text] [Related]
4. Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
Sachse MM; Wagner G
Br J Dermatol; 2014 Feb; 170(2):475-7. PubMed ID: 24117280
[No Abstract] [Full Text] [Related]
5. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
6. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.
Wakimoto H; Harada K; Arai T; Maeda T; Irisawa R; Tsuboi R
Int J Dermatol; 2017 Feb; 56(2):e33-e35. PubMed ID: 27805257
[No Abstract] [Full Text] [Related]
11. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
12. [BRAF mutation detection in metastatic melanoma].
Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
[No Abstract] [Full Text] [Related]
13. [Treatment of metastatic melanoma with BRAF inhibitors].
Hafner C
Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
[No Abstract] [Full Text] [Related]
14. FDA approves vemurafenib for treatment of metastatic melanoma.
Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
[No Abstract] [Full Text] [Related]
15. Eruptive keratoacanthoma and squamous cell carcinoma complicating imiquimod therapy: response to oral acitretin.
Foxton G; Delaney T
Australas J Dermatol; 2011 Feb; 52(1):66-9. PubMed ID: 21332698
[TBL] [Abstract][Full Text] [Related]
16. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
Lang N; Weisser A; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
[No Abstract] [Full Text] [Related]
18. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
[No Abstract] [Full Text] [Related]
19. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
20. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]